Health Care · Pharmaceutical Preparations · NYSE · CIK 1739104 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $26.39Day +3.41%Mkt cap $13.2B1Y +83.4%Off 52W high −4.8%Vol (1Y) 43.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,970 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.2% of sh out |
| Days to cover8.4d |
| 13F net flow (QoQ)−6.67% |
| Top-10 13F concentration63.5% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.89B |
| Earnings (TTM)-$242.0M |
| ROE−3.7% |
| Net margin−4.9% |
| Debt / equity0.57× |
| Sales growth 3Y2.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+16.6% |
| 1Y+83.4% |
| 3Y+118.6% |
| 5Y−27.9% |
| Since incept. (ann.)−3.9% |
Total return through 2026-07-29 · series begins 2018-09-20. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)43.6% |
| Ann. volatility (3Y)47.7% |
| Sharpe (1Y)1.59 |
| Sharpe (3Y)0.79 |
| Max drawdown (1Y)−26.2% |
| Max drawdown (3Y)−56.1% |
| Beta (3Y vs SPY)2.17 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Dodge & Cox | 68.9M | $1.6B | — | −12.8% |
| FMR LLC | 50.9M | $1.2B | — | −2.4% |
| BlackRock, Inc. | 47.6M | $1.1B | — | +2.8% |
| PRIMECAP MANAGEMENT CO/CA/ | 45.8M | $1.1B | — | −0.8% |
| T. Rowe Price Investment Management, Inc. | 34.6M | $829M | — | −33.3% |
| DIMENSIONAL FUND ADVISORS LP | 24.5M | $587M | — | −2.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 22.6M | $542M | — | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 22.3M | $535M | — | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (545,274,868) exceed the cover-page shares-outstanding count for this quarter (497,168,077, as of 2026-02-19) by more than securities-lending double counting can explain (FINRA short interest 24,342,462 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.11 | −15.4% | $1.37B | +14.9% |
| 2025-12-31 | 2026-02-24 | — | — | $1.14B | +12.2% |
| 2025-09-30 | 2025-11-05 | −$0.07 | −109.6% | $1.14B | +10.4% |
| 2025-06-30 | 2025-08-07 | $0.02 | — | $1.24B | +4.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
